Patients with Adenocarcinoma or Large Cell Carcinoma Histologies Achieved Improvement in Overall Survival when Treated with ALIMTA-based Regimen
INDIANAPOLIS, May 28 /PRNewswire-FirstCall/ -- The type of non-small cell lung cancer (NSCLC) patients have may now influence their treatment regimen and, in turn, survival outcome according to the results of a major study published online in the Journal of Clinical Oncology. Publication of the study was announced by Eli Lilly and Company.
The 1,725-patient study, the largest Phase III clinical trial in the first-line NSCLC setting, evaluated ALIMTA(R) (pemetrexed for injection) plus cisplatin versus GEMZAR(R) (gemcitabine HCl for injection) plus cisplatin, a standard of treatment in this setting. The trial met its primary endpoint of non-inferiority relative to overall survival.
Additionally, in a pre-planned histological analysis, patients with either adenocarcinoma or large-cell carcinoma had a statistically superior and clinically relevant improvement in overall survival when treated with the pemetrexed regimen in the first-line setting.
In comparison, patients with squamous cell histology were found to have a more favorable overall survival when treated with the gemcitabine regimen.
"While non-small cell lung cancer has typically been treated as one disease, this study confirms that histology, or tumor type, can provide a clue as to which treatment regimen works best for a particular tumor type," said the study's lead author, Giorgio Scagliotti, M.D., Department of Clinical and Biological Sciences Thoracic Oncology Unit, University of Torino, Orbassano, Italy. "If we can tailor the therapy for better results, we are closer to improving outcomes for this terrible disease."
The overall survival of patients treated with either the pemetrexed
regimen or gemcitabine regimen was found to be non-inferior, with a median
survival of 10.3 months. However, when researchers reviewed
|SOURCE Eli Lilly and Company|
Copyright©2008 PR Newswire.
All rights reserved